Center-Authored Papers

Filters: Author is Sandhu, Vicky  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Veatch JR, Sandhu V, Becker PS, Pagel JM, Appelbaum FR, Estey E.  2013.  The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia.. Blood. 122(2):293-4.
S
Shadman M, Mawad R, Dean C, Chen TL, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS et al..  2015.  Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.. American journal of hematology. 90(6):483-6. Abstract
M
Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L et al..  2016.  Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.. British journal of haematology. 172(2):238-245. Abstract
Mawad R, Gooley TA, Sandhu V, Lionberger J, Scott B, Sandmaier BM, O'Donnell P, Becker PS, Petersdorf S, Dorcy KS et al..  2013.  Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(31):3883-8. Abstract
G
Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, Appelbaum FR, Estey EH, Fang M.  2015.  Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.. Cancer. Abstract
D
Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, Nicoud I, Dahlberg A, Bernstein ID, Appelbaum FR et al..  2016.  Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.. The Lancet. Haematology. 3(7):e330-9. Abstract
B
Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K et al..  2015.  A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.. British journal of haematology. Abstract
Bar M, Othus M, Park HM, Sandhu V, Chen X, Wood BL, Estey E.  2015.  Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.. Leukemia & lymphoma. 56(11):3109-3115. Abstract
A
Araki D, Othus M, Walter RB, Sandhu V, Sandmaier BM, Becker PS, Appelbaum FR, Estey EH.  2015.  Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.. Haematologica. 100(7):e254-6.
Araki D, Othus M, Walter RB, Becker PS, Sandhu V, Estey EH.  2015.  Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy? Leukemia & lymphoma. :1-3.